Menu

New Vaccines and Novel Monoclonal Antibody Treatments on the Frontline of COVID-19

When:
October 11, 2021 @ 8:43 am – October 11, 2022 @ 9:43 am
2021-10-11T08:43:00+00:00
2022-10-11T09:43:00+00:00

New Vaccines and Novel Monoclonal Antibody Treatments on the Frontline of COVID-19

View Activity

FACULTY PRESENTERS

Shyam Kottilil, MD, PhD
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC

PROGRAM OVERVIEW

This enduring activity will review clinical trial data on the efficacy and safety of monoclonal antibodies and vaccines authorized for use in the treatment and prevention of COVID-19, and highlight and address healthcare disparities during the COVID-19 pandemic.

TARGET AUDIENCE

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists who treat and manage underserved patient populations.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Evaluate clinical trial data of vaccines and monoclonal antibody therapies for the prevention and treatment of COVID-19.
  • Select appropriate treatment for managing mild-to-moderate COVID-19 for people with certain pre-existing conditions.
  • Explain the efficacy and safety of approved vaccinations and monoclonal antibody treatments to patients
  • Incorporate tools and resources developed to promote safe and responsible use of infusion therapies for the treatment of patients with COVID-19.
  • Explain COVID-19 related initiatives and programs aimed at lessening health disparities in underserved communities.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19. Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Shyama Kottilil, MD, PhD Discloses that the University of Maryland has received funds to participate in clinical trials, and he has received research funds paid to the university from Merck, Gilead Sciences, and Arbutus Biopharma. He has served on the advisory boards of Merck Inc and Regeneron Pharmaceuticals.

William A. Fischer II, MD Discloses that he has been contracted for research for Ridgeback Biopharmaceuticals for COVID-19 research, as well as consulted for Merck and Roche. He also worked for Syneos and Janssen for adjudication of AE in RSV and influenza studies respectively, and served as the site PI for the Phase I Lilly study of bamlanivimab and for the Phase II study of casirivimab/imdevimab at University of North Carolina.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]. Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill